摘要
分析1例肺肉瘤样癌(PSC)患者的影像学检查资料,通过CT引导下肺部肿块穿刺确诊,基因检测诊断为晚期肺癌肉瘤并EML4-ALK融合。予以克唑替尼靶向治疗后,疾病控制时间为5个月,总生存时间为210天。通过复习近年来国内外的PSC相关文献,总结其最新治疗进展。
The imaging data of a case of pulmonary sarcomatoid carcinoma(PSC)were analyzed.The patient was diagnosed by CTguided pulmonary mass puncture,and further verified by gene detection,and was diagnosed as advanced pulmonary sarcomatoid carcinoma with ELM4-ALK fusion.The patient was treated with crizotinib,and had a disease control time of 5 months and a total survival time of 210 days.In this paper,we also reviewed the literatures about pulmonary sarcomatoid carcinoma,and summarized the latest progress in the treatment of pulmonary sarcomatoid carcinoma.
作者
刘利
杨农
LIU Li;YANG Nong(Department of Lung Cancer and Gastroenterology,Hunan Cancer Hospital/the Affiliated Cancer Hospital of Xiangya School of Medicine,Central South University,Changsha,Hunan,410006,China)
出处
《肿瘤药学》
CAS
2020年第3期376-380,共5页
Anti-Tumor Pharmacy
关键词
肺肉瘤样癌
基因检测
靶向治疗
免疫治疗
Pulmonary sarcomatoid carcinoma
Gene detection
Targeted therapy
Immunotherapy
